Event driven interest in Globus Medical

Globus Medical (GMED) is back in focus after commentary that its stock, up 60.1% over the past three years, still looks undervalued even as pricing pressure on hospitals and payers weighs on sentiment.

That combination of strong historical total returns, a P/E ratio below industry averages, and reported improvement in adjusted EBITDA margins is prompting investors to reassess what they are paying for Globus Medical’s earnings power today.

Over the past year Globus Medical has paired a 41.6% total shareholder return with a 12.6% 30 day share price gain, which signals that momentum has picked up again after earlier weakness this year as investors reassess the stock against its current P/E and margin profile.

If you are comparing Globus Medical with other potential ideas in the sector, this is a useful moment to scan for peers that are also leveraging automation and data in healthcare using the 40 healthcare AI stocks.

Bulls point to Globus Medical’s below industry P/E and reported EBITDA margin strength. Bears focus on hospital pricing pressure and the stock’s sharp multi year run. Which side do the current valuation checks support next?

Most Popular Narrative: 17% Undervalued

On the most followed narrative, Globus Medical’s fair value of $103.23 sits comfortably above the last close at $85.67, which frames the current debate around its earnings power and margin profile.

Continued innovation and adoption of robotics, navigation, and minimally invasive procedures, including expansion of the ExcelsiusGPS ecosystem, launch of the Excelsius XR headset, and a robust product pipeline, position Globus to capitalize on healthcare digitization trends, driving higher ASPs, stronger market differentiation, and improved gross margins over time.

Want to see what this robotics push really assumes for Globus Medical? The narrative leans on tighter margins, steadier revenue growth and a valuation multiple that needs those forecasts to land.

Result: Fair Value of $103.23 (UNDERVALUED)

However, Globus Medical still faces real pressure if hospital capital spending stays muted or if NuVasive and Nevro integration fails to deliver the expected cost and margin benefits.

Next Steps

Given the mixed sentiment around Globus Medical, this is a good time to look through the numbers yourself and act while the debate is fresh. To see what investors view as the key upsides, review the 5 key rewards.

Looking for more investment ideas beyond Globus Medical?

If Globus Medical has sharpened your focus on quality, do not stop here. Use the Simply Wall Street Screener to uncover more stocks that fit your approach.

• Target income opportunities by scanning for companies with stronger yields and stable profiles using the 12 dividend fortresses.
• Hunt for potential value by reviewing companies that combine quality fundamentals with appealing pricing through the 50 high quality undervalued stocks.
• Reduce portfolio stress by focusing on companies with steadier profiles and lower risk scores using the 78 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.